



**Principles to Promote the
Quality of Life of People
with Multiple Sclerosis**



multiple sclerosis
international federation



Published by:

Multiple Sclerosis International Federation

ISBN 0-9550139-0-9

Prepared by:

Michael Trisolini, Ph.D., M.B.A.

Joshua Wiener, Ph.D.

RTI International, Waltham, Massachusetts & Washington, U.S.A.

Deborah Miller, Ph.D.

Cleveland Clinic Foundation, Cleveland, Ohio, U.S.A.

RTI International is an independent nonprofit research organization dedicated to conducting research and development that improves the human condition. With a staff of more than 2,500 people, RTI offers innovative research and technical solutions to governments and businesses worldwide in the areas of health and pharmaceuticals, advanced technology, surveys and statistics, education and training, economic and social development, and the environment. For more information visit www.rti.org.

Cover photographs provided by Amelia Davis from her book "My Story: A Photographic Essay On Life With Multiple Sclerosis." (Copyright Amelia Davis © 2002), which can be ordered from www.ameliadavisphotography.com or demosmedpub.com

Acknowledgments

With special appreciation to:

Interviewees

Michael Barnes	Professor of Neurological Rehabilitation, University of Newcastle upon Tyne, UK
Kathryn Brennan	Member National Programmes Advisory Council, National MS Society, USA
Sandy Burnfield	Board Member UK MS Trust, UK
Sanjay Chadha	Board Member UK MS Society, UK
Peggy Crawford	Clinical Psychologist, Mellen Center for Multiple Sclerosis, USA
Jeremy Hobart	Neurological Outcome Measures Unit, Institute of Neurology, UK
Vanessa Hodges	Member National Programmes Advisory Council, National MS Society, USA
Ludwig Kappos	University Hospital, Basel & Medical Director Swiss MS Society, Switzerland
Peter Kaskel	University of Ulm, Germany
Susan Kushner	Associate Professor of Physical Therapy, Slippery Rock University, USA
Dawn Langdon	Clinical Neuropsychologist and Senior Lecturer, University of London, UK

Ian McDonald	Founder Member Sylvia Lawry Centre for MS Research, Honorary Board member Multiple Sclerosis International Federation, Emeritus Professor of Clinical Neurology at the Institute of Neurology, UK
Nancy C. Smith	Advanced practice nurse, Mellen Center for Multiple Sclerosis Treatment and Research, USA
Lael Stone	Medical Director, Mellen Center for Multiple Sclerosis Treatment and Research, USA
Alan Thompson	Medical Director, Neurorehabilitation Unit, Clinical Director & Director of Research and Development at the Institute of Neurology, UK
Athanasios Vidalis	Department of Psychiatry, Hippocratio Hospital, Greece
Nikki Ward	Lecturer Practitioner in MS, Faculty of Health and Community Care, University of Central England, UK
Oversight Group	
Mike O'Donovan, (Chair)	Chief Executive, UK MS Society
Eva Havrdová	Chairman, Czech MS Society Medical Advisory Board
Hans-Peter Hartung	Department of Neurology, Heinrich-Heine-University, Germany

Tom Houle	Member National Advisory Board of Persons with MS. National MS Society, USA
Nicholas G. LaRocca	Director Health Care Delivery and Policy Research, National MS Society, USA
Nancy Law	Vice President, Client Programmes Department, National MS Society, USA
Elizabeth McDonald	Medical Director, MS Society of Australia
Xavier Montalbán	Director, Unit of Clinical Neuroimmunology, Hospital Universitari Vall d'Hebron, Spain
Christine Purdy	Chief Executive, Multiple Sclerosis International Federation
Mateja de Reya	Chief Executive, Slovenian MS Society
Peter Rieckmann	Head of Clinical Research Unit for MS and Neuroimmunology, University of Würzburg, Germany
Paul Rompani	Deputy Chief Executive, Multiple Sclerosis International Federation
Alan Thompson	Medical Director, Neurorehabilitation Unit, Clinical Director & Director of Research and Development at the Institute of Neurology, UK
Susan Tilley	Chair, Multiple Sclerosis International Federation Persons with MS International Committee

Work Group

Mike Dugan	Chief Executive, National MS Society, USA
Nicholas G. LaRocca	Director Health Care Delivery and Policy Research, National MS Society, USA
Nancy Law	Vice President, Client Programmes Dept. National MS Society, USA
Christine Purdy	Chief Executive, Multiple Sclerosis International Federation
Paul Rompani	Deputy Chief Executive, Multiple Sclerosis International Federation
Susan Tilley	Chair, MSIF Persons with MS International Committee

Others

Megan Burgess	MS Nurse Consultant, Hope Hospital, UK
Caron Caldwell	Acting MS Nurse Fund Programme Manager, UK MS Society, UK
Pedro Carrascal	Chief Executive, Spanish MS Federation, Spain
Francisco Delgado	Chief Executive, Spanish MS Society, Spain
Peter Flachenecker	Chairman Neurological Rehabilitation Center Quellenhof, Germany
Marieluise Gilch	Chief Executive, Bavaria Chapter, German MS Society, Germany
Cristina Gómez Ortiz	Board Member Spanish MS Society, Spain
Maria Jose Flores	Spanish MS Society, Spain

Natasa Koudouni	Aerobic Trainer, Greek MS Society, Greece
Graham Love	Chief Executive, MS Society of Ireland, Ireland
Kostas Michalakis	Chief Executive, Greek MS Society, Greece
Allen O'Connor	Chairman, MS Society of Ireland, Ireland
Izabella Odrobinska	Chief Executive, Polish MS Society, Poland
Anastasios Orologas	President, Greek MS Society, Greece
Mahi Orologas	Greek MS Society, Greece
Maria Pilar Resta	Spanish MS Society, Spain
Dorothea Pitschnau-Michel	Chief Executive, German MS Society, Germany
Alun White	Board Member UK MS Society, UK
Christiane Zahn	Bavaria Chapter, German MS Society, Germany

In addition to the interviewees, Oversight Group members, Work Group members and others specifically mentioned above MSIF would like to thank the following for their support in developing the QOL Principles: MSIF's International Medical & Scientific Board, Persons with MS International Committee and Member Society staff and volunteers, Consortium of MS Centers, International Organization of MS Nurses and the numerous people affected by MS and health professionals who provided valuable comments and suggestions. Most of all MSIF would like to thank Biogen Idec for their shared vision and commitment to improving the quality of life of people with and affected by multiple sclerosis.




Contents

Foreword	10
Preface	12
Multiple Sclerosis International Federation	14
Introduction	16
The Principles	
Independence and Empowerment	20
Medical Care	23
Continuing (Long-Term or Social) Care	27
Health Promotion and Disease Prevention	28
Support for Family Members	30
Transportation	32
Employment and Volunteer Activities	33
Disability Benefits and Cash Assistance	36
Education	37
Housing and Accessibility of Buildings in the Community	38
References	40

Annexes

Annex 1	WHO QOL Domains Matrix	62
Annex 2	Number of supporting references by level of evidence	63



Foreword



Photo: Richard Young

My mother was 35 when she was diagnosed with MS. At first life went on much as usual. Her one admission that she had the illness was very much in character: she read everything she could about it. But none of her pamphlets or booklets could tell her why she had the illness or how severely her life would be affected. I would estimate that my mother saw a physiotherapist

less than 10 times in the 10 years following her diagnosis. She lived in the country and couldn't drive; for a very brief period a physiotherapist came to visit her, but that somehow fell through, and the physiotherapist stopped coming. The same thing happened with the home help who was sent once Mum had given up work and was reduced to crawling upstairs instead of walking. There never seemed to be quite enough money to provide services for people with MS; the only option was to be hospitalised.

It was not only the rapid progression of the illness that affected my mother - and us, her family. It was the rapid deterioration of the quality of her life, her self-esteem, her independence.

Quality of life is something we must all fight for in every

country around the world, and to fight we need tools that are appropriate to the battle ahead. That is why the Principles to Promote the Quality of Life of People with MS in this document are so

to apply them in your community and your nation. I wish you every success as you fight to improve the quality of life of people affected by MS around the world.

“Quality of life is something we must all fight for in every country around the world, and to fight we need tools that are appropriate to the battle ahead.”

important. They provide points of aspiration for all affected by MS, and their strategic application is an essential part of helping groups and individuals focus on what is best for their community. Beyond that, workshops and internet communication will allow a sharing of experiences and a building of best practice internationally. This document is only a beginning. The continuing impact of the Principles will come from your determination



J.K.Rowling

Preface



As early as 1947 the World Health Organization (WHO) described health as a “state of complete physical, mental and social well being, and not merely the absence of disease or infirmity.” However, most health care services in the past focused on the treatment of a disease and its symptoms rather than paying attention to the whole person. Fortunately today, health care is shifting from a disease-oriented

approach to one centred on the patient’s experience and needs, with issues such as access to health care, independence and empowerment, employment, education and many other elements holding equal weight in assessing an individual’s wellbeing.

With the aid of 15 collaborating centres around the world, WHO developed the WHOQOL-100 framework. In this, WHO defines Quality of Life as an individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns. It is a broad ranging concept, affected by the person’s physical health, psychological state, level of independence, social relationships and to salient features of their environment.

The WHOQOL-100 framework was intended as a tool for general use in medical practice, research, audit and policy making. We are particularly pleased therefore to see that the

comprehensive yet tangible focus for national MS Societies as they develop and implement plans to improve the quality of life of those affected by this life-long disease.

“These Principles provide a comprehensive yet tangible focus for national MS Societies as they develop and implement plans to improve the quality of life of those affected by this life-long disease.”

Multiple Sclerosis International Federation (MSIF) has incorporated the WHOQOL domains into their Principles intended to affect policy, and to improve the lives of people affected by multiple sclerosis.

MSIF is one of the NGOs “in official relations with the World Health Organization”, and I am in full support of the way MSIF has taken WHO's work another step forward. These Principles provide a

**Benedetto Saraceno, MD
Director Department
of Mental Health and
Substance Abuse
World Health Organization**



MSIF

The Multiple Sclerosis International Federation

The **Multiple Sclerosis International Federation (MSIF)** was established in 1967 as an international body linking the work of national MS Societies worldwide.

Together we share the global vision of a world without MS. That's why we also work with the international scientific community to stimulate international collaborative research. In the meantime however, MSIF continues to support people affected by MS in a variety of ways.


We communicate best practice knowledge, experience and information on all aspects of MS and in a variety of languages. This helps people affected by MS make their own choices and decisions.

We also aim to improve the services offered worldwide, so we actively encourage and support the development of effective and efficient national MS societies wherever there is a prevalence of MS. Another worldwide initiative is our support for advocacy

campaigns to influence public policy in favor of people with MS.

Our various activities are underpinned by good governance and leadership, transparent financial and administrative structures, and a healthy fundraising capacity.

As a person with MS myself I have first-hand experience of the impact MS can have on quality of life, not only for the individual with MS but also for family and friends. By producing the Principles to Promote the Quality of Life of People with MS, MSIF leads the global MS movement, and I am honoured to be a part of it.



Sarah Phillips
Chairman & President
Multiple Sclerosis
International Federation



Introduction

Multiple sclerosis (MS) is a chronic, disabling disease affecting approximately 2.5 million people worldwide. Although the impact of the disease varies with the type of MS, with the individual, and often from day-to-day, common symptoms include fatigue, bladder and bowel disorders, vision problems, tremor, spasticity, abnormal speech, swallowing disorders, sexual dysfunction, difficulty performing basic everyday activities, (such as eating, bathing, dressing, and housekeeping,) cognitive impairment, mobility problems, pain and depression. As a result of these symptoms, MS can substantially and adversely affect an individual's quality of life (QOL). In addition, many people with MS leave the labour force and must depend

on relatives or government programmes for financial and other support.

To enhance the lives of people with MS, this report presents “principles” to improve their QOL. While these principles include health care, they reach far beyond medical care to a broad range of other domains. Moreover, these principles are not primarily focused on assessing or measuring QOL. Rather, they are designed to guide the development and evaluation of services and programmes that are provided by governments, for-profit and nonprofit health and social service providers, employers, and other organizations for people with MS.


These principles are also designed to be used by international organizations, national MS societies, people with MS and their families, governments, health and continuing care providers, researchers, businesses and others to evaluate existing and proposed services and programmes and to advocate for improvements.

The principles are problem-based. As such, they focus on the common issues that affect QOL for people with MS, for instance the distress and disability caused by the many symptoms of the disease, the inability in some cases to live at home, the loss of paid employment, the loss of mobility, and the lack of coordination between medical and social care. As a result,

the principles are not linked to particular types or stages of MS.

It should always be kept in mind that the ultimate goal is a cure for MS. However, until a cure is found and can be broadly implemented, it is important to work to maintain or improve QOL for people with MS, utilizing a broad range of approaches such as those described in these principles.

The development of the principles was based on a series of interviews, a literature review, the clinical, programmatic, and research experience of the authors, and review by a Work Group and technical Oversight Group organized by the Multiple Sclerosis International Federation (MSIF).





The interviews were conducted with a range of international MS and QOL experts, MS clinical providers and people with MS; a list of people interviewed is presented in the Acknowledgements. The Oversight Group and Work group includes MS experts and people with MS representing a range of MSIF member countries; the members of the Oversight Group and Work Group are listed in the Acknowledgements.

The literature review included relevant journal articles, MS clinical textbooks, publications of national MS societies, and relevant web-based publications; a list is included in the References section. The References section also includes a level of evidence assigned to each publication.

The level of evidence definitions used in this literature review are as follows:

- 1a** Meta-analysis of randomized controlled trials
- 1b** Randomized controlled trial
- 2a** Controlled study, without randomization
- 2b** Quasi-experimental study
- 3** Non-experimental, descriptive study (e.g., comparative study, correlation study, case study)
- 4** Expert committee report, opinion and/or experience of respected authority

The principles are presented in a way that reflects the state of affairs when they have been fulfilled. This active voice is meant to empower people with MS and move away from passive formulations in which things are done “to” or “for” people with MS. Thus, the principles describe programmes and policies that work well and meet the needs of people with MS rather than being exhortations of what things “should be” done.

The principles are organized into the following ten themed sections:

- Independence and Empowerment
- Medical Care
- Continuing (Long-Term or Social) Care
- Health Promotion and Disease Prevention
- Support for Family Members
- Transportation
- Employment and Volunteer Activities
- Disability Benefits and Cash Assistance
- Education
- Housing and Accessibility of Buildings in the Community

Development of the principles was guided, in part, by the first five domains included in the World Health Organization's QOL framework, including physical health, psychological health, level of independence, social relations, and the

environment. They were used as references to ensure that the scope of the principles would include all aspects of QOL relevant to people with MS. The WHOQOL domains addressed by each principle are indicated in a table in Annex 1.

Each section begins with a general statement supporting its theme and an introductory discussion of key issues. The principles are then presented in numbered paragraphs. Citations at the end of each principle indicate the references that provide supporting evidence. A summary of the number of supporting references for each principle by level of evidence is included in a table in Annex 2.



The Principles

1.0 Independence and Empowerment

People with MS are empowered as full participants in their communities and in decision-making about the management and treatment of the disease.

MS is a complicated disease that has a major impact on quality of life (QOL). It is important that programmes, policies and services enable people with MS to be as independent as possible and have control over their lives. The day-to-day uncertainty that many people with MS experience often causes a significant loss of QOL. To retain independence and empowerment, people with MS must be able to participate fully in their communities, in management and decision-making regarding their disease, and not be restricted in their treatments by financial liabilities. Governments should have legislation that protects their rights.

1.1. People with MS must be able to realize their full potential. They should have the opportunity to travel to places outside of the home, work at jobs, acquire an education, and do the other things that people without disabilities do. They should have the opportunity to participate in community life as much as is possible and desired. ¹⁻³¹

1.2. People with MS and their families must be involved in decisions about their medical treatment and other decisions that affect their lives. Even when there is cognitive impairment in the person with MS, the affected person and his or her family must be involved in the decision-making

process to the fullest extent possible. They should collaborate closely with their physicians and other health care providers. 1,3,4,6,7,17,23,30,32-42

1.3. People with MS and their families have choices regarding their medical treatment and the other services they receive. Because each person is different, services must be tailored to the individual needs and choices of each person, and a broad range of services made available. 1,3,4,34,43-45

1.4. People with MS should have access to treatments, programmes, and services without regard to their ability to pay. 1,3,4,27,46-48

1.5. People with MS must be empowered to take control of the decisions affecting their lives and to self-manage the disease as much as possible. To encourage the highest possible degree of self-management, they should be able to access a broad range of information, advice, and education regarding the nature of MS, its treatment, and methods for improving QOL. Access to this information is to be made available through multiple sources, including books, pamphlets, websites, and health and social service professionals. Mutual or peer support opportunities should also be available to people with MS. 1,3-5,7,12,13,17,19,22,23,25-27,30,32-35,37-40,42,45-47,49-65



1.6. Legislation must be enacted that protects the rights of people with MS and other people with disabilities against discrimination in all aspects of social and community life. Enforcement of these laws is to be consistent and effective. Among other things, these laws require governments, employers, building owners, transportation organizations, and others to make reasonable adjustments to improve accessibility for people with disabilities. These laws are to ensure that people with MS have access to all types of financial instruments, including current accounts and savings accounts, credit cards, insurance, loans, and all forms of financial assistance. ^{1,4,9,12,13,17,20,26-28,35,42,46,47,66,67}



2.0. Medical Care

People with MS have access to medical care, treatments and therapies appropriate to their needs.


MS is a serious condition, making access to medical care extremely important to the QOL of people with the disease. The wide range of symptoms and functional impairments that often accompany MS means that a broad array of services is needed. In addition, the twin facts that it is a long-term illness and that primary care providers may not treat many people with the disease result in a need for continuity of care by professionals who have specialized knowledge about treatment of MS. Because the time of initial diagnosis is particularly stressful, it deserves special attention from health care and other providers. Also because expert medical care is essential for people with MS, they must have access to

necessary health care services including excellent diagnostic services, knowledgeable and skilled medical providers, up-to-date drugs and medical treatments and services that address their symptomatic needs.

2.1. Access to Health Care

2.1.1. All people with MS must have access to evidence-based, quality health care. ^{1,3,4,24,35,47,68}

2.1.2. Health care for people with MS includes medically-effective treatments, including symptom and disease modifying drugs, rehabilitation services, appropriate and affordable enabling technology that is tailored to the needs of people with MS, and continuing care services.



Medically-effective and culturally-appropriate treatments to manage the symptoms of MS must be made available. 2-4,6,7,11,16,17,19,24,32,35,37,42,44,45,47,53,56,57,59,61,69,71-128

2.2. Initial Diagnosis

2.2.1. Physicians must be sensitive to the major psychological, social, financial, vocational and medical impact of telling a person that she or he has MS. Patients must have adequate time to ask questions of the physician. Newly diagnosed patients should be referred to the national MS Society and an MS nurse specialist or other health professional with MS treatment and counselling experience. 1,12,30,32,33,35,36,40,42,47,56,103,117,129-134

2.2.2. At the time of the initial diagnosis, people with MS must have access to information about MS that is specific to newly diagnosed individuals, together with information on local and national medical, support, rehabilitation, and life-planning services. 1,30,35,36,42,54,56,63,103,106,114,133

2.3 Physicians, Nurses, Hospitals and Other Medical Providers

2.3.1. Medical care is to be provided by clinicians who have expertise in MS, including neurologists. In order to ensure prompt and expert treatment of the wide range of symptoms and disabilities that people with MS may experience, both care and case management must be provided by multidisciplinary teams that specialize in MS. 1,3,4,6,16,17,27,35,42,61,65,68,103,115,119,122,124,125,128

2.3.2. As appropriate, people with MS must be offered a broad range of services beyond those provided by physicians and nurses, including physical, occupational, and speech therapy, counselling, and other services. The purpose and potential benefits of those services are to be clearly explained to them. 1-,6,11,16,17,24,35-37,42,44,45,47,53,56,59,61,65,68,71-74,76-78,81,86,90,94-104,106,109,111-119,121-128,135-138

2.3.3. Medical facilities, such as hospitals, must take into account and make reasonable modifications of physical facilities and equipment to accommodate the physical disabilities of people with MS, including difficulty walking, bathing, and getting on and off examining tables. 3,35,135


2.3.4. Treatment for MS must be co-ordinated with treatment for other acute and chronic medical conditions and with

continuing care needs. Protocols for referrals and transferring responsibility among different providers and health care organizations should be agreed upon by all relevant parties. Services are seamless from the patient's perspective. 3,27,30,35,42,124,125,128

2.3.5. People with MS must have continuity of care with their clinical providers over an extended period of time. The focal point for continuity is a provider with sufficient time and motivation to learn about each patient's individual experience with MS, to listen to the patient's questions and concerns, and to explore the full range of symptoms. This provider could be an MS nurse specialist, a physician knowledgeable about MS, or another health professional who specializes in MS care.

1,3,4,7,12,30,33,35,54,57,65,103,137





2.3.6. All neurologists, primary care physicians, nurses, and other health professionals who work with people with MS must have the goal of promoting QOL, and not just clinical management of the disease.

1,3,4,6,12,18,19,27,30,40,45,48,49,56,65,70-72,74,76,94-97,99-102,138,139

2.4. Symptom Management

2.4.1. Medically-effective and culturally-appropriate treatments must be available to address the symptoms of MS, including (but not limited to) fatigue, depression, cognitive impairment, impaired sexual function, pain, bladder and bowel dysfunction, limited mobility, vision problems, and others. Health professionals must consider in a systematic way whether a person with MS has additional, sometimes “hidden” symptoms or problems that can affect QOL.

2-4,6,7,11,16,17,19,20,35-37,40,42,44,45,47,48,53,56,57,59,61,65,68-70,72,76-78,82,90,95-99,101-103,105,106,109,110,112,113,115-119,121,122,124-128,135-137,140-152



3.0 Continuing (Long-Term or Social) Care

People with MS have access to a wide range of age-appropriate care services that enable them to function as independently as possible.

Continuing care refers to nursing home care, respite care, home health care, personal care, adult day care, and other services designed to address functional impairments, such as the inability to eat, bathe, or dress oneself. Continuing care services allow people with MS who have disabilities to function more independently. QOL for people with MS is greatly enhanced when principles for home and community based care, residential care, and adequate financial remuneration for care-givers are supported.

3.1. People with MS must have access to a wide range of home, community based and respite care services that help

individuals reside in their homes as long as possible.

4,8,10,20,35,42,47,81,86,103,115,153,154

3.2. Institutional or residential services, such as nursing homes, should be used only if home and community based care is no longer appropriate. Services in these institutional facilities must be designed to take account of the interests and needs of people with MS, who are typically younger than other residents. 35,42,47,103,155-157

3.3. Paid professional continuing care providers must receive adequate training in the specific features of MS, and adequate pay, fringe benefits, and supervision.



4.0. Health Promotion and Disease Prevention

People with MS have the information and services they need to maintain positive health practices and a healthy lifestyle.

Medical care often dominates the services provided to people with MS yet there are a number of other activities and services that promote wellness and prevent other diseases. Health promotion activities include relaxation techniques, stress management, energy conservation techniques, cooling therapy, aerobic, mobility, and balance exercises, and other wellness practices.

Disease prevention includes immunizations (e.g., influenza) and other routine medical services (e.g., pap smears). People with disabilities have been found to have less access to preventive care services, due to a variety of physical and other types of barriers.

4.1. People with MS must be offered quality information and training for a wide range of health promotion practices, depending on patient preferences and their effectiveness in enhancing QOL for the individual.

1,3,5,7,17,24,25,31,35,36,45,47,51,53,55,56,59-61,104,124,126-128,142,148-150,158-165

4.2. Good nutrition and physical fitness must be encouraged for people with MS by their clinical providers and counsellors.

1,3,6,16,17,24,35,36,45,47,51,53,56,59,61,76,104,112,122,124,126-

4.3. Physicians should not over-emphasize MS care at the expense of health promotion and disease prevention. People with MS must be provided with routine preventive medical care.

1,3,6,7,36,42,56,160,168

5.0 Support for Family Members

Family members and caregivers receive information and support to mitigate the effects of MS.

Most MS-related services are provided to the person with MS by family members and other informal carers, who are also profoundly affected by having a relative or friend with MS. These family and friends benefit from services designed to help them cope with the stress and other impacts associated with the disease.

Children can be affected by having a parent with MS and may not fully understand the reasons for a parent's health problems, think they have somehow caused them or feel neglected as a member of the family. The effort required to maintain an effective parenting role despite the symptoms and disabilities of MS can be a major source of stress for people with MS. Conversely, maintaining a meaningful role

as a parent can be a source of enhanced QOL. These principles acknowledge and address the special needs of care-givers to help maintain their quality of life when a person has MS.

5.1. Services and training must be available to family members and other informal carers affected by MS as well as to the person with MS. They must also be provided with information about available community services that may provide support. ^{1,3,7,8,10,15,17,20,35,42,47,53,58,64,109,114,117,130,169-185}

5.2. Respite care must be available to relieve the burden on family members and other informal carers. It should be available either in the home or in institutions providing continuing care. 1,3,15,35,47,103,126,130,180,183-185

5.3. Family members and other informal caregivers must be routinely evaluated regarding their caregiving-related physical and emotional stress and other personal needs. 1,3,15,35,42,47,103,117,127,130,136,169-182,184,185

5.4. People with MS and their families must have access to family and relationship counselling. 1,3,6,15,17,23,25,35,37,42,47,53,55,57,58,106,109,113,130,152,169-182,184,185

5.5. Services must be available to people with MS to aid them in their parenting responsibilities. Children are to be protected from taking on inappropriate roles as caregivers for parents with MS. 1,3,6,25,31,35,37,47,126,130,152,174

5.6. Services must be available to prevent physical, financial, and psychological abuse of people with MS by family members and other informal caregivers. 1,3,117,130,184

6.0 Transportation

People with MS have access to their communities through accessible public transportation and assistive technology for personal automobiles.

Mobility for people with MS can be greatly enhanced when they continue to drive or when alternative transportation is available. People with MS may have difficulty with transportation because of their functional disabilities, cognitive impairment and use of mobility aids, yet public transportation, often their only available resource, is sometimes not available or difficult to use. Lack of transportation can mean that people with MS remain inside their homes, inhibiting their ability to participate in life in the community.

6.1. Services should be available to enable people with MS to continue driving their own cars as long as possible, if desired. ^{3,6,15,17,30,47,124,165}


6.2. For people with MS who cannot or do not drive, accessible transportation services must be available and affordable. ^{3,6,35,47}

7.0 Employment and Volunteer Activities

Support systems and services are available to enable people with MS to continue employment as long as they are productive and desire to work.

Many people with MS leave the labour force because of the symptoms of the disease, such as fatigue, functional disability, and cognitive impairment. Leaving the workforce can have a major effect on family income as well as an individual's self-esteem. Some people with MS could continue to work if employers provide assistance and restructure their work.

A wide range of accommodations or adaptations are possible, including part-time work, additional breaks in the work day, working only mornings, reducing the room temperature, changing work tasks, telecommuting, reducing travel, providing ramps, providing offices near restrooms, and others. Governments and social service providers can contribute by providing vocational rehabilitation and training programmes.




For those people with MS who do leave the labour force, substitute activities are important to sustain a sense of purpose in life. Examples include voluntary activities, creative arts, serving as MS peer counsellors, assisting with MS Society or MS centre administration or advocacy efforts, pursuing further education, and others.

7.1. Services must be available to allow people with MS to continue employment as long as they are productive and desire to work. 3,6,9,12,13,15,17,19,20,25-28,30,35,42,46-48,56,59,65-67,124,152,165,186-189

7.2. Employers must provide job modifications and other adaptations or accommodations to enable people with MS to continue working. Employers must be educated about the nature and symptoms of MS, and how job modifications can often enable people with MS to remain productive employees for many years. 3,9,12,13,15,17,19,20,26-28,35,37,38,42,46,47,56,65-67,124,152,165,186-189

7.3. Employers should provide time off for family members and other informal care-givers to accommodate the unexpected needs of people with MS. Employers should be educated about the roles of family members in treating and managing acute exacerbations and symptoms of MS. 3,13,15,19,28,37,47,189



7.4. Vocational rehabilitation and training services must be available to help people with MS return or stay in the labour force, if desired. 3,6,12,13,26-28,35,42, 46,47,65-67,124,152,186,187

7.5. When people with MS do retire from paid employment, they must be provided counselling and encouragement to develop alternative, voluntary activities that can fill the void often left by the loss of work. The transition out of paid employment is to be planned well in advance to ensure people with MS receive all of the services to which they are entitled, to prepare for alternate occupations or activities, and to avoid the stress that may accompany abrupt, unplanned transitions from work to retirement.

3,8,20,21,25,37,42,189

8.0 Disability Entitlements and Cash Assistance

Disability entitlements and services are available to those in need, provide an adequate standard of living, and have flexibility to allow for the disease variability that is characteristic of multiple sclerosis.

Many people with MS who leave the labour force are dependent on disability entitlements and means-tested cash assistance for their income. Thus, the eligibility standards, payment levels and administration of these entitlements have a direct impact on the QOL of people with MS. These principles address the importance of this type of financial assistance, including the application process, level of support and flexibility in administration that can greatly affect the well-being of people with MS.

8.1. Eligibility criteria and application procedures for public and private disability entitlements and means-tested cash assistance must be fair and not unduly burdensome nor restrictive. ^{27,28,46,67}

8.2. Cash payment levels for public and private disability benefits and means-tested cash assistance must be high enough for people with MS to have an adequate standard of living. ^{8,15,28,46,48,67,190}

8.3. Disability entitlements must be flexible, allowing for partial disability, to enable people with MS to take time off when needed or to continue working part-time, if desired. ^{9,28,47,66,67}

9.0. Education

MS does not inhibit the education of people with MS, their families or careers.

In a modern economy, education is critical to obtain good jobs. In addition, participating in the education of one's children is a central role of being a parent. In order to participate in these activities, people with MS need educational institutions to accept their disabilities and accommodate their special needs. For example, they can allow people with MS to take classes in the morning when fatigue is less, reduce classroom temperature, allow tape recording or note takers for people with cognitive disabilities and provide distance learning opportunities.

9.1. Schools, colleges and other educational institutions must provide assistance for people with MS when needed, to enable them to pursue education to the extent of their abilities. ^{15,19}

9.2. Schools, colleges and other educational institutions must be physically accessible to people with disabilities, including people with MS.

9.3. Schools must provide assistance to parents with MS when needed so that they can participate in their children's student programmes, in school volunteer activities, and in parent-teacher conferences.

10.0 Housing and Accessibility of Buildings in the Community

Accessibility, both of public buildings and in the availability of accessible homes and apartments, is essential to independence for people with MS.

Because many people with MS have disabilities that limit their mobility and require use of ambulatory aids, scooters and/or wheelchairs, a great deal of housing and buildings in the community are not accessible or easy to use.

For example, buildings and homes that require going up and down stairs often mean that substantial parts of the house or building cannot be used by a person in a wheelchair. A basic need for people with MS is for housing and buildings that address their special concerns and provide access to services they need and activities they desire.



10.1. Housing

10.1.1. People with MS must have access to basic adaptations of their homes, to enable them to reside in the community as long as possible.

3,8,38,42,47,124,165,191

10.1.2. People with MS must not be restricted from loans, grants, or other forms of financial assistance for making home adaptations because of their disease. 3,8,38

10.1.3. A significant proportion of all new housing must be accessible from initial design and construction and not require adaptations to achieve accessibility for people with MS.

3,8,38,191

10.2. Accessibility of Buildings in the Community

10.2.1. Buildings in the community, especially government offices and educational settings, must be accessible to people with MS.

8,47,57

10.2.2. New public buildings must be designed and built for accessibility to people with MS and other disabilities. 3,8,57

References

1. Defriez M, Griffiths D, Millett C. The perception of the current provision of care for multiple sclerosis sufferers in the community. *Primary health care res develop* 2003; 4(3):233-43. Level of Evidence: 3
2. Ford HL, Gerry E, Johnson MH, et al. Health status and quality of life of people with multiple sclerosis. *Disabil rehabil* 2001; 23(12):516-21. Level of Evidence: 3
3. Neri M, Kroll T. Understanding the consequences of access barriers to health care: experiences of adults with disabilities. *Disabil rehabil* 2003; 25(2):85-96. Level of Evidence: 3
4. Welburn J. Co-ordinating specialists care packages for people with multiple sclerosis. *Community nurse* 2000; 6(7):11-2. Level of Evidence: 4
5. Barnwell AM, Kavanagh DJ. Prediction of psychological adjustment to multiple sclerosis. *Soc sci med* 1997; 45(3):411-8. Level of Evidence: 3
6. Britell C, Burks J, Schapiro R. Chapter 12: Introduction to symptom and rehabilitative management: disease management model. in: Burks J, Johnson K, eds. *Multiple sclerosis: diagnosis, medical management, and rehabilitation*. New York: Demos Medical Publishing, Inc, 2000. Level of Evidence: 4
7. Burks J. Multiple sclerosis care: an integrated disease-management model. *J Spinal cord med* 1998; 21(2):113-6. Level of Evidence: 4
8. Dyck I. Hidden geographies: the changing lifeworlds of women with multiple sclerosis. *Soc sci med* 1995; 40(3):307-20. Level of Evidence: 3
9. Dyck I, Jongbloed L. Women with multiple sclerosis and employment issues: a focus on social and institutional environments. *Can J Occup ther* 2000; 67(5):337-46. Level of Evidence: 3

10. Finlayson M. Concerns about the future among older adults with multiple sclerosis. *Am J Occup ther* 2004; 58(1):54-63. Level of Evidence: 3
11. Forwell S. Managing the ordinary things of everyday life. *MS in focus* 2003; 1:9-11. Level of Evidence: 4
12. Gordon P, Lewis MD, Wong D. Multiple sclerosis: strategies for rehabilitation counselors. *J Rehabil* 1994; 60(3):34-8. Level of Evidence: 3
13. Gordon PA, Feldman D, Shipley B, et al. Employment issues and knowledge regarding ADA of persons with multiple sclerosis. *J Rehabil* 1997; 63(4):52-8. Level of Evidence: 3
14. Gulick EE. Correlates of quality of life among persons with multiple sclerosis. *Nurs res* 1997; 46(6):305-11. Level of Evidence: 3
15. Hakim E, Bakheit A, Bryant T, et al. The social impact of multiple sclerosis - a study of 305 patients and their relatives. *Disabil rehabil* 2000; 22(6):288-93. Level of Evidence: 3
16. Haselkorn J, Leer S, Hall J, et al. Chapter 17: Mobility. in: Burks J, Johnson K, eds *Multiple sclerosis: diagnosis, medical management, and rehabilitation*. New York: Demos Medical Publishing, Inc., 2000. Level of Evidence: 4
17. Holland N, Murray T, Reingold S. *Multiple sclerosis: a guide for the newly diagnosed*. Second edition. New York: Demos Medical Publishing, Inc., 2002. Level of Evidence: 4
18. Hopman W, Coo H, Brunet D, et al. Longitudinal assessment of health-related quality of life (HRQL) of patients with multiple sclerosis. *Inter J of MS care* 2000; 2(4):3. Level of Evidence: 3
19. Johnson K, Yorkston K, Klasner E, et al. The cost and benefits of employment: a qualitative study of experiences of persons with multiple sclerosis. *Arch phys med rehabil* 2004; 85(2):201-9. Level of Evidence: 3

20. Leino-Kilpi H, Luoto E, Katajisto J. Elements of empowerment and MS patients. *J Neurosci nurs* 1998; 30(2):116-23. Level of Evidence: 3
21. Lundmark P, Branholm IB. Relationship between occupation and life satisfaction in people with multiple sclerosis. *Disabil rehabil* 1996; 18(9):449-53. Level of Evidence: 3
22. McCabe MP, McKern S. Quality of life and multiple sclerosis: comparison between people with multiple sclerosis and people from the general population. *J Clin psychol med settings* 2002; 9(4):287-95. Level of Evidence: 3
23. Mohr DC, Dick LP, Russo D, et al. The psychosocial impact of multiple sclerosis: exploring the patient's perspective. *Health psychol* 1999; 18(4):376-82. Level of Evidence: 3
24. O'Hara L, De Souza L, Ide L. A Delphi study of self-care in a community population of people with multiple sclerosis. *Clin rehabil* 2000; 14(1):62-71. Level of Evidence: 3
25. Reynolds F, Prior S. Sticking jewels in your life: exploring women's strategies for negotiating an acceptable quality of life with multiple sclerosis. *Qualitative health research [Special Issue: Care of Self]* 2003; 13(9):1225-51. Level of Evidence: 3
26. Roessler R, Rumrill P. Strategies for enhancing career maintenance self-efficacy of people with multiple sclerosis. *J Rehabil* 1994; 60(4):54-9. Level of Evidence: 4
27. Rumrill P, Roessler RT, Koch LC. Surveying the employment concerns of people with multiple sclerosis: a participatory action research approach. *J Voc rehabil* 1999; 12(2): 75-82. Level of Evidence: 3
28. Rumrill P, Tabor TL, Hennessey ML, et al. Issues in employment and career development for people with multiple sclerosis: meeting the needs of an emerging vocational rehabilitation clientele. *J Voc rehabil, [Special Issue: Rehabilitation Counseling in the 21st Century]* 2000; 14(2):109-17. Level of Evidence: 4

29. Schwartz CE, Sendor M. Helping others helps oneself: response shift effects in peer support. *Soc sci med* 1999; 48(11):1563-75. Level of Evidence: 3
30. Somerset M, Sharp D, Campbell R. Multiple sclerosis and quality of life: a qualitative investigation. *J Health serv res policy* 2002; 7(3):151-9. Level of Evidence: 3
31. Multiple Sclerosis Society of Australia. MS and parenting. Lidcombe: 1996. Level of Evidence: 4
32. Forbes A, While A, Dyson L, et al. Impact of clinical nurse specialists in multiple sclerosis - synthesis of the evidence. *J Adv nurs* 2003; 42(5):442-62. Level of Evidence: 4
33. Courts NF, Buchanan EM, Werstlein PO. Focus groups: the lived experience of participants with multiple sclerosis. *J Neurosci nurs* 2004; 36(1):42-7. Level of Evidence: 3
34. Department of Health. The expert patient: a new approach to chronic disease management for the 21st Century. London: 2001. Level of Evidence: 4
35. Freeman J, Ford H, Mattison P, et al. Developing MS healthcare standards: evidence-based recommendations for service providers. London: The Multiple Sclerosis Society of Great Britain and Northern Ireland, 2002. Level of Evidence: 4
36. Giesser B. Talking about the diagnosis of multiple sclerosis. New York: National Multiple Sclerosis Society, 2003. Level of Evidence: 4
37. Halper J, Holland N. Meeting the challenge of multiple sclerosis, Part 2. *Am J Nurs* 1998; 87(11):39-45. Level of Evidence: 4
38. McLaughlin J, Zeeberg I. Self-care and multiple sclerosis: a view from two cultures. *Soc sci med* 1993; 37(3):315-29. Level of Evidence: 3

39. Somerset M, Peters TJ, Sharp DJ, et al. Factors that contribute to quality of life outcomes prioritised by people with multiple sclerosis. *Qual life res* 2003; 12(1):21-9. Level of Evidence: 2b
40. Thorne S, Con A, McGuinness L, et al. Health care communication issues in multiple sclerosis: an interpretive description. *Qual health res* 2004; 14(1):5-22. Level of Evidence: 3
41. Yorkston KM, Johnson K, Klasner ER, et al. Getting the work done: a qualitative study of individuals with multiple sclerosis. *Disabil rehabil* 2003; 25(8):369-79. Level of Evidence: 3
42. National Collaborating Centre for Chronic Conditions. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. Clinical guideline 8. London: National Institute for Clinical Excellence [Web Page]. 2003; Available at www.nice.org.uk. (Accessed 15 February 2004). Level of Evidence: 4
43. Somerset M, Campbell R, Sharp D, et al. What do people with MS want and expect from health-care services? *Health expect* 2001; 4(1):29-37. Level of Evidence: 3
44. Saunders A, Aisen M. Chapter 26: Sexual dysfunction. in: Burks J, Johnson K, eds. *Multiple sclerosis: diagnosis, medical management, and rehabilitation*. New York: Demos Medical Publishing, Inc, 2000. Level of Evidence: 4
45. Schapiro R. *Managing the symptoms of multiple sclerosis*. Fourth edition. New York: Demos Medical Publishing, 2003. Level of Evidence: 4
46. Roessler RT, Rumrill PD, Hennessey ML, et al. Perceived strengths and weaknesses in employment policies and services among people with multiple sclerosis: results of a national survey. *J Prevent assess rehabil* 2003; 21(1):25-36. Level of Evidence: 3
47. Rumrill P, Hennessey M. *Multiple sclerosis: a guide for rehabilitation and health care professionals*. Springfield: Charles C Thomas Publisher, 2001. Level of Evidence: 3

48. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: part II: quality of life. *Can J Neurol sci* 1998; 25(1):31-8. Level of Evidence: 3
49. Miller DM, Rudick RA, Baier M, et al. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. *Mult scler* 2003; 9(1):1-5. Level of Evidence: 2b
50. Peters T, Somerset M, Campbell R, et al. Variables associated with attendance at, and the perceived helpfulness of, meetings for people with multiple sclerosis. *Health soc care community* 2003; 11(1):19-26. Level of Evidence: 3
51. Stuifbergen AK, Becker H, Blozis S, et al. A randomized clinical trial of a wellness intervention for women with multiple sclerosis. *Arch phys med rehabil* 2003; 84(4):467-76. Level of Evidence: 1b
52. Baker LM. Sense making in multiple sclerosis: the information needs of people during an acute exacerbation. *Qual health res* 1998; 8(1):106-20. Level of Evidence: 3
53. Bashir K, Whitaker J. *Handbook of multiple sclerosis*. New York: Lippincott Williams & Wilkins, 2002. Level of Evidence: 4
54. Box V, Hepworth M, Harrison J. Identifying information needs of people with multiple sclerosis. *Nurs times* 2003; 99(49):32-6. Level of Evidence: 3
55. Crigger NJ. Testing an uncertainty model for women with multiple sclerosis. *Adv Nurs sci* 1996; 18(3):37-47. Level of Evidence: 3
56. Joy J, R Johnston, eds. *Multiple sclerosis: current status and strategies for the future*. Washington, DC: National Academy Press, 2001. Level of Evidence: 4
57. Koch T, Kelly S. Understanding what is important for women who live with multiple sclerosis. *Aust J Holist nurs* 1999; 6(1):14-24. Level of Evidence: 3

58. Miller CM. The lived experience of relapsing multiple sclerosis: a phenomenological study. *J Neurosci nurs* 1997; 29(5):294-304. Level of Evidence: 3
59. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. *Mult scler* 2003; 9(1):63-72. Level of Evidence: 4
60. O'Hara L, Cadbury H, De Souza L, et al. Evaluation of the effectiveness of professionally guided self-care for people with multiple sclerosis living in the community: a randomized controlled trial. *Clin rehabil* 2002; 16(2):119-28. Level of Evidence: 1b
61. Polman C, Thompson A, Murray T, McDonald W. Multiple sclerosis: the guide to treatment and management. Fifth edition. New York: Demos Medical Publishing, 2001. Level of Evidence: 4
62. Schwartz CE. Teaching coping skills enhances quality of life more than peer support: results of a randomized trial with multiple sclerosis patients. *Health psychol* 1999; 18(3):211-20. Level of Evidence: 1b
63. Slade A, Tennant A, Ford H. Meeting the information needs of people with multiple sclerosis. *Int J Therapy rehab* 2003; 10(5):211-7. Level of Evidence: 3
64. Vaughan R, Morrison L, Miller E. The illness representations of multiple sclerosis and their relations to outcome. *Br J Health psychol* 2003; 8 (Pt 3):287-301. Level of Evidence: 3
65. Multiple Sclerosis Society of Great Britain and Northern Ireland. Basics of best practice in the management of multiple sclerosis. London: 1999. Level of Evidence: 4
66. O'Day B. Barriers for people with multiple sclerosis who want to work: a qualitative study. *J Neurol rehabil* 1998; 12(3):139-46. Level of Evidence: 3
67. Multiple Sclerosis Society of Canada. Assets and abilities: your guide to work, income security, and multiple sclerosis. Toronto: 2001. Level of Evidence: 4

68. De Broe S, Christopher F, Waugh N. The role of specialist nurses in multiple sclerosis: a rapid and systematic review. *Health technol assess* 2001; 5(17):1-37. Level of Evidence: 3
69. Thompson AJ. Progress in neurorehabilitation in multiple sclerosis. *Curr opin neurol* 2002; 15(3):267-70. Level of Evidence: 4
70. McReynolds CJ, Koch LC, Rumrill JrP. Psychosocial adjustment to multiple sclerosis: Implications for rehabilitation professionals. *J Voc rehabil* 1999; 12(2):83-91. Level of Evidence: 4
71. Ko Ko C. Effectiveness of rehabilitation for multiple sclerosis. *Clin rehabil* 1999; 13 Suppl 1:33-41. Level of Evidence: 4
72. Jonsson A, Dock J, Ravnborg MH. Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis. *Acta neurol scand* 1996; 93(4):229-35. Level of Evidence: 3
73. Freeman JA, Langdon DW, Hobart JC, et al. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? *Neurology* 1999; 52(1):50-6. Level of Evidence: 3
74. Thompson AJ. The effectiveness of neurological rehabilitation in multiple sclerosis. *J Rehabil res dev* 2000; 37(4):455-61. Level of Evidence: 4
75. Arnoldus JH, Killestein J, Pfenning LE, et al. Quality of life during the first 6 months of interferon-beta treatment in patients with MS . *Mult scler* 2000; 6(5):338-42. Level of Evidence: 2b
76. Bethoux F. Chapter 43: Rehabilitation in multiple sclerosis. in: Cohen J, Rudick R, eds. *Multiple sclerosis therapeutics*. Second edition. London: Martin Dunitz Ltd, 2003. Level of Evidence: 4

77. Bethoux F, Miller DM, Kinkel RP. Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life. *Mult scler* 2001; 7(2):137-42. Level of Evidence: 2b
78. Schwid SR, Petrie MD, Murray R, et al. A randomized controlled study of the acute and chronic effects of cooling therapy for MS. *Neurology* 2003; 60(12):1955-60. Level of Evidence: 1b
79. Cohen JA, Cutter GR, Fischer JS et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. *Neurology* 2002; 59(5):679-87. Level of Evidence: 1b
80. Freeman JA, Thompson AJ, Fitzpatrick R, et al. Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. *Neurology* 2001; 57(10):1870-5. Level of Evidence: 1b
81. Freeman JA, Thompson AJ. Community services in multiple sclerosis: still a matter of chance. *J Neurol neurosurg psychiatry* 2000; 69(6):728-32. Level of Evidence: 3
82. Gianino JM, York MM, Paice JA, et al. Quality of life: effect of reduced spasticity from intrathecal baclofen. *J Neurosci nurs* 1998; 30(1):47-54. Level of Evidence: 3
83. Granger CV, Wende K, Brownscheidle CM. Use of the FIM instrument in a trial of intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis. *Am J Phys med rehabil* 2003; 82(6):427-36. Level of Evidence: 1b
84. Kobelt G, Jönsson L, Fredrikson S. Cost-utility of interferon beta-1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. *Eur J Health econom* 2003; 4:50-9. Level of Evidence: 2b
85. Multiple Sclerosis Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: evidence-based management strategies for disease modifying therapies in multiple sclerosis. Paralyzed Veterans of America, 2001. Level of Evidence: 4

86. Pozzilli C, Brunetti M, Amicosante AM, et al. Home based management in multiple sclerosis: results of a randomised controlled trial. *J Neurol neurosurg psychiatry* 2002; 73(3):250-5. Level of Evidence: 1b
87. Rice G, Incorvaia B, Munari L et al. Interferon in relapsing-remitting MS. *Cochrane database of systematic reviews*. Issue 4 edition. Chichester, UK: John Wiley & Sons, Ltd., 2001. Level of Evidence: 1a
88. Rice GP, Oger J, Duquette P, et al. Treatment with interferon beta-1b improves quality of life in multiple sclerosis. *Can J Neurol sci* 1999; 26(4):276-82. Level of Evidence: 2b
89. Schwartz CE, Coulthard-Morris L, Cole B, et al. The quality-of-life effects of interferon beta- 1b in multiple sclerosis. An extended Q-TWiST analysis. *Arch Neurol* 1997; 54(12):1475-80. Level of Evidence: 2b
90. Schwid S. Chapter 42: Management of cognitive impairment in multiple sclerosis. in: Cohen J, Rudick R, eds. *Multiple sclerosis therapeutics*. Second edition. London: Martin Dunitz Ltd, 2003. Level of Evidence: 4
91. Shawaryn MA, Schiaffino KM, LaRocca NG, et al. Determinants of health-related quality of life in multiple sclerosis: the role of illness intrusiveness. *Mult scler* 2002; 8(4):310-8. Level of Evidence: 3
92. Vermersch P, de Seze J, Stojkovic T, et al. Interferon beta1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability. *J Neurol* 2002; 249(2):184-7. Level of Evidence: 2b
93. Zivadinov R, Zorzon M, Tommasi M, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. *J Neurol sci* 2003; 216(1):113-8. Level of Evidence: 3

94. Solari A, Filippini G, Gasco P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. *Neurology* 1999; 52(1):57-62. Level of Evidence: 1b
95. Sitzia J, Haddrell V, Rice-Oxley M. Evaluation of a nurse-led multidisciplinary neurological rehabilitation programme using the Nottingham Health Profile. *Clin Rehabil* 1998; 12(5):389-94. Level of Evidence: 2b
96. Patti F, Ciancio MR, Cacopardo M, et al. Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients - a randomised controlled trial. *J Neurol* 2003; 250(7):861-6. Level of Evidence: 1b
97. Kidd D, Howard RS, Losseff NA, et al. The benefit of inpatient neurorehabilitation in multiple sclerosis. *Clin Rehabil* 1995; 9(3):198-203. Level of Evidence: 2b
98. Freeman JA, Langdon DW, Hobart JC, et al. The impact of inpatient rehabilitation on progressive multiple sclerosis. *Ann Neurol* 1997; 42(2):236-44. Level of Evidence: 1b
99. Di Fabio RP, Choi T, Soderberg J, et al. Health-related quality of life for patients with progressive multiple sclerosis: influence of rehabilitation. *Phys Ther* 1997; 77(12):1704-16. Level of Evidence: 2a
100. Di Fabio R, Soderberg J, Choi T, et al. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. *Arch Phys Med Rehabil* 1998; 79(2):141-6. Level of Evidence: 2a
101. Craig J, Young CA, Ennis M, et al. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. *J Neurol Neurosurg Psychiatry* 2003; 74(9):1225-30. Level of Evidence: 1b
102. Aisen ML, Sevilla D, Fox N. Inpatient rehabilitation for multiple sclerosis. *J Neurol Rehabil* 1996; 10(1):43-6. Level of Evidence: 2b

103. Barnes MP, Gilhus NE, Wender M. Task force on minimum standards for health care of people with multiple sclerosis: June 1999. *Eur J Neurol* 2001; 8(3):215-20. Level of Evidence: 4
104. Benito-Leon J, Morales JM, Rivera-Navarro J, et al. A review about the impact of multiple sclerosis on health-related quality of life. *Disabil Rehabil* 2003; 25(23):1291-303. Level of Evidence: 4
105. Dierich M. Chapter 24: Bladder dysfunction. in: Burks J , Johnson K, eds. *Multiple sclerosis: diagnosis, medical management, and rehabilitation*. New York: Demos Medical Publishing, Inc, 2000. Level of Evidence: 4
106. Foley F. *Talking about sexual dysfunction*. New York: National Multiple Sclerosis Society, 2003. Level of Evidence: 4
107. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. *Neurology* 2002; 58(2):169-78. Level of Evidence: 4
108. Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. *Eur J Neurol* 2001; 8(1):27-35. Level of Evidence: 3
109. Holland N. *Talking about elimination problems*. New York: National Multiple Sclerosis Society, 2003. Level of Evidence: 4
110. Janardhan V. , Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. *J Neurol sci* 2002; 205(1):51-8. Level of Evidence: 3

111. Jeffery D. Chapter 23: Pain and dysethesia. in: Burks J , Johnson K, eds. Multiple sclerosis: diagnosis, medical management, and rehabilitation. New York: Demos Medical Publishing, Inc, 2000. Level of Evidence: 4
112. Krupp L, Elkins L. Chapter 14: Fatigue. in: Burks J, Johnson K, eds. Multiple sclerosis: diagnosis, medical management, and rehabilitation. New York: Demos Medical Publishing, Inc., 2000. Level of Evidence: 4
113. LaRocca N. Chapter 22: Cognitive and emotional disorders. in: Burks J, Johnson K, eds. Multiple sclerosis: diagnosis, medical management, and rehabilitation. New York: Demos Medical Publishing, Inc., 2000. Level of Evidence: 4
114. LaRocca N. Talking about cognitive dysfunction. New York: National Multiple Sclerosis Society, 2003. Level of Evidence: 4
115. Litta R. Changing relationships and roles within the family. MS in Focus 2004; 3:9-11. Level of Evidence: 4
116. Logemann J. Chapter 28: Dysphagia. in: Burks J, Johnson K, eds. Multiple sclerosis: diagnosis, medical management, and rehabilitation. New York: Demos Medical Publishing Inc. , 2000. Level of Evidence: 4
117. Minden S. Talking about depression and other emotional changes. New York: National Multiple Sclerosis Society, 2003. Level of Evidence: 4
118. Minden S, Frumin M, Erb J. Chapter 39: Treatment of disorders of mood and affect in multiple sclerosis. in: Cohen J, Rudick R, eds. Multiple sclerosis therapeutics. Second edition. London: Martin Dunitz Ltd, 2003. Level of Evidence: 4
119. Motta R. How to find strategies to manage the unpredictable. MS in focus 2003; 2:10-4. Level of Evidence: 4

120. Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. *J Neurol Neurosurg Psychiatry* 1998; 65(4):460-6. Level of Evidence: 3
121. Patti F, Ciancio MR, Reggio E, et al. The impact of outpatient rehabilitation on quality of life in multiple sclerosis. *J Neurol* 2002; 249(8):1027-33. Level of Evidence: 1b
122. Rizzo M. Chapter 40: Treatment of pain, paresthesias, and paroxysmal disorders in multiple sclerosis. in: Cohen J, Rudick R, eds. *Multiple sclerosis therapeutics*. Second edition. London: Martin Dunitz Ltd, 2003. Level of Evidence: 4
123. Samkoff L, Goodman A. Chapter 34: Disease modifying drug therapy for multiple sclerosis in clinical practice. in: Cohen J, Rudick R, eds. *Multiple sclerosis therapeutics*. Second edition. London: Martin Dunitz Ltd, 2003. Level of Evidence: 4
124. Multiple Sclerosis Council for Clinical Practice Guidelines. *Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis*. Paralyzed Veterans of America, 1998. Level of Evidence: 4
125. Multiple Sclerosis Council for Clinical Practice Guidelines. *Urinary dysfunction and multiple sclerosis: evidence-based management strategies for urinary dysfunction in multiple sclerosis*. Paralyzed Veterans of America, 2001. Level of Evidence: 4
126. Multiple Sclerosis Society of Ireland. *Diagnosed with MS?* Dublin: 2003. Level of Evidence: 4
127. Multiple Sclerosis Society of Ireland. *Taking control of your emotions*. Dublin: 2003. Level of Evidence: 4
128. National Multiple Sclerosis Society. *Management of MS-related fatigue*. expert opinion paper. New York: National Multiple Sclerosis Society [Web Page]. 2002; Available at www.nationalmssociety.org. (Accessed 17 April 2003). Level of Evidence: 4

129. Brechin M, Burgess M. Designing an education tool for MS patients. *Prof nurse* 2001; 16(11):1471-4. Level of Evidence: 4
130. Janssens A, van Doorn P, de Boer J, et al. Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners. *Acta neurol Scand* 2003; 108(6):389-95. Level of Evidence: 2b
131. Johnson J. On receiving the diagnosis of multiple sclerosis: managing the transition. *Mult scler* 2003; 9(1):82-8. Level of Evidence: 2b
132. Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. *J Neurol neurosurg psychiatry* 2000; 68(2):144-9. Level of Evidence: 2b
133. Porter B, Keenan E. Nursing at a specialist diagnostic clinic for multiple sclerosis. *Br J Nurs* 2003; 12(11):650-6. Level of Evidence: 4
134. Vermersch P, de Seze J, Delisse B, et al. Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment. *Mult scler* 2002; 8(5):377-81. Level of Evidence: 2b
135. Vanage SM, Gilbertson KK, Mathiowetz V. Effects of an energy conservation course on fatigue impact for persons with progressive multiple sclerosis. *Am J Occup ther* 2003; 57(3):315-23. Level of Evidence: 2b
136. Barrett M. *Sexuality and multiple sclerosis*. Toronto: Multiple Sclerosis Society of Canada, 1999. Level of Evidence: 4
137. Heerings M. The role of the MS nurse. *MS in focus* 2003; 1 :14-6. Level of Evidence: 4
138. Rothwell PM , McDowell Z, Wong CK, et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. *Be med J* 1997; 314(7094):1580-3. Level of Evidence: 3

139. Benito-Leon J, Morales JM, Rivera-Navarro J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. *Eur J Neurol* 2002; 9(5):497-502. Level of Evidence: 3
140. Amato MP, Ponziani G, Rossi F, et al. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. *Mult scler* 2001; 7(5):340-4. Level of Evidence: 3
141. National Multiple Sclerosis Society. Disease management consensus statement. New York: National Multiple Sclerosis Society [Web Page]. 2002; Available at www.nationalmssociety.org. (Accessed 13 March 2003). Level of Evidence: 4
142. Mathiowetz V, Matuska KM, Murphy ME. Efficacy of an energy conservation course for persons with multiple sclerosis. *Arch phys med rehabil* 2001; 82(4):449-56. Level of Evidence: 1b
143. Flensner G, Lindencrona C. The cooling-suit: case studies of its influence on fatigue among eight individuals with multiple sclerosis. *J Adv nurs* 2002; 37(6):541-50. Level of Evidence: 3
144. Foley FW, LaRocca NG, Sanders AS, et al. Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. *Mult scler* 2001; 7(6):417-21. Level of Evidence: 2b
145. Fruehwald S, Loeffler-Stastka H, Eher R, et al. Depression and quality of life in multiple sclerosis. *Acta neurol Scand* 2001; 104(5):257-61. Level of Evidence: 3
146. Metz LM, Patten SB, Archibald CJ, et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. *J Neurol neurosurg psychiatry* 2004; 75(7):1045-7. Level of Evidence: 3
147. Mohr D, Cox D. Multiple sclerosis: empirical literature for the clinical health psychologist. *J Clin psychol* 2001; 57(4):479-99. Level of Evidence: 4




148. Ward N, Winters S. Results of a fatigue management programme in multiple sclerosis. *Br J Nurs* 2003; 12(18):1075-80. Level of Evidence: 2b
149. Kasser SL, Stuart ME. Psychological well-being and exercise behavior in persons with and without multiple sclerosis. *Clin Rehabil* 2001; 15(4):81-6. Level of Evidence: 3
150. Beatus J, O'Neill JK, Towesend T, et al. The effect of a one-week retreat on self-esteem, quality of life, and functional ability for persons with multiple sclerosis. *Neurol Rep* 2002; 26(3):154-9. Level of Evidence: 2b
151. Consortium of Multiple Sclerosis Centers. Multiple sclerosis quality of life inventory: technical supplement. New York: National Multiple Sclerosis Society, 1997. Level of Evidence: 3
152. Multiple Sclerosis International Federation. MS - the disease [Web Page]. Available at www.msif.org. (Accessed 7 June 2004). Level of Evidence: 4
153. Devitt R, Chau B, Jutai JW. The effects of wheelchair use on the quality of life of persons with multiple sclerosis. *Occup Ther Health Care* 2003; 17(3/4):63-79. Level of Evidence: 3
154. Blake DJ, Bodine C. An overview of assistive technology for persons with multiple sclerosis. *J Rehabil Res Dev* 2002; 39(2):299-312. Level of Evidence: 4
155. Flynn S. Multiple sclerosis: the treetops model of residential care. *Br J Nurs* 2002; 11(9):635-42. Level of Evidence: 3
156. Buchanan RJ, Wang S, Ju H. Analyses of the minimum data set: comparisons of nursing home residents with multiple sclerosis to other nursing home residents. *Mult Scler* 2002; 8(6):512-22. Level of Evidence: 3
157. Buchanan R, Lewis K. Services that nursing facilities should provide to residents with MS: a survey of health professionals. *Rehabil Nurs* 1997; 22(2):67-72. Level of Evidence: 4

158. Sutherland G, Andersen MB, Stoove MA. Can aerobic exercise training affect health-related quality of life for people with multiple sclerosis? *J Sport exercise psychol* 2001; 23(2):122-35. Level of Evidence: 1b
159. Stuifbergen AK, Roberts GJ. Health promotion practices of women with multiple sclerosis. *Arch phys med rehabil* 1997; 78(12 Suppl 5):S3-9. Level of Evidence: 2b
160. Stuifbergen AK, Seraphine A, Roberts G. An explanatory model of health promotion and quality of life in chronic disabling conditions. *Nurs res* 2000; 49(3):122-9. Level of Evidence: 3
161. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. *Neurology* 2004; 62(11):2058-64. Level of Evidence: 1b
162. Mostert S, Kesselring J. Effects of a short-term exercise training programme on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. *Mult scler* 2002; 8(2):161-8. Level of Evidence: 1b
163. Husted C, Pham L, Hekking A, et al. Improving quality of life for people with chronic conditions: the example of t'ai chi and multiple sclerosis. *Altern ther health med* 1999; 5(5):70-4. Level of Evidence: 3
164. Becker H, Stuifbergen A. What makes it so hard? Barriers to health promotion experienced by people with multiple sclerosis and polio. *Fam community health* 2004; 27(1):75-85. Level of Evidence: 3
165. Rogers S. Things I wish someone had told me: practical thoughts for people newly diagnosed with multiple sclerosis. Lidcombe: MS Society of Australia. Level of Evidence: 4
166. Stuifbergen AK. Physical activity and perceived health status in persons with multiple sclerosis. *J Neurosci nurs* 1997; 29(4):238-43. Level of Evidence: 3

167. Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. *Ann neurol* 1996; 39(4):432-41. Level of Evidence: 1b
168. Cheng E, Myers L, Wolf S, et al. Mobility impairments and use of preventive services in women with multiple sclerosis: observational study. *BMJ* 2001; 323(7319):968-9. Level of Evidence: 3
169. Schwartz L, Kraft GH. The role of spouse responses to disability and family environment in multiple sclerosis. *Am J Phys med rehabil* 1999; 78(6):525-32. Level of Evidence: 3
170. Rivera-Navarro J, Morales-Gonzalez JM, Benito-Leon J. Informal caregiving in multiple sclerosis patients: data from the Madrid Demyelinating Disease Group study. *Disabil rehabil* 2003; 25(18):1057-64. Level of Evidence: 3
171. Sato A, Ricks K, Watkins S. Needs of caregivers of clients with multiple sclerosis. *J Community health nurs* 1996; 13(1):31-42. Level of Evidence: 3
172. McKeown LP, Porter-Armstrong AP, Baxter GD. Caregivers of people with multiple sclerosis: experiences of support. *Mult scler* 2004; 10(2):219-30. Level of Evidence: 3
173. McKeown LP, Porter-Armstrong AP, Baxter GD. The needs and experiences of caregivers of individuals with multiple sclerosis: a systematic review. *Clin rehabil* 2003; 17(3):234-48. Level of Evidence: 4
174. Harrison T, Stuifbergen A. Disability, social support, and concern for children: depression in mothers with multiple sclerosis. *J Obstet gynecol neonatal nurs* 2002; 31(4):444-53. Level of Evidence: 3
175. Hainsworth MA. Helping spouses with chronic sorrow related to multiple sclerosis. *J Psychosoc nurs ment health serv* 1996; 34(6):36-40. Level of Evidence: 3

176. Gregory RJ, Disler P, Firth S. Caregivers of people with multiple sclerosis: a survey in New Zealand. *Rehabil nurs* 1996; 21(1):31-7. Level of Evidence: 3
177. Dewis ME, Niskala H. Nurturing a valuable resource: family caregivers in multiple sclerosis. *Axone* 1992; 13(3):87-94. Level of Evidence: 3
178. Chipchase SY, Lincoln NB. Factors associated with carer strain in carers of people with multiple sclerosis. *Disabil rehabil* 2001; 23(17):768-76. Level of Evidence: 3
179. Cheung J, Hocking P. The experience of spousal carers of people with multiple sclerosis. *Qual health res* 2004; 14(2):153-66. Level of Evidence: 3
180. Boeije H, Duijnste M, Grypdonck M. Continuation of caregiving among partners who give total care to spouses with multiple sclerosis. *Health soc care community* 2003; 11(3):242-52. Level of Evidence: 3
181. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. *Neurology* 1997; 48(1):74-80. Level of Evidence: 3
182. Aronson KJ, Cleghorn G, Goldenberg E. Assistance arrangements and use of services among persons with multiple sclerosis and their caregivers. *Disabil rehabil* 1996; 18(7):354-61. Level of Evidence: 3
183. Cockerill R, Warren S. Care for caregivers: the needs of family members of MS patients. *J Rehabil* 1990; 56(1):41-4. Level of Evidence: 3
184. Miller D. Caring for the carers. *MS in Focus* 2004; 3:12-6. Level of Evidence: 4
185. Carton H, Loos R, Pacolet J, et al. A quantitative study of unpaid caregiving in multiple sclerosis. *Mult scler* 2000; 6(4):274-9. Level of Evidence: 3

186. Beatty WW, Blanco CR, Wilbanks SL, et al. Demographic, clinical, and cognitive characteristics of multiple sclerosis patients who continue to work. *J Neurol Rehabil* 1995; 9(3):167-73. Level of Evidence: 3
187. Busche KD, Fisk JD, Murray TJ, et al. Short term predictors of unemployment in multiple sclerosis patients. *Can J Neurol Sci* 2003; 30(2):137-42. Level of Evidence: 3
188. Fraser RT, Johnson EK, Clemmons DC, et al. Vocational rehabilitation in multiple sclerosis (MS): a profile of clients seeking services. *Work* 2003; 21(1):69-76. Level of Evidence: 3
189. Jongbloed L . Factors influencing employment status of women with multiple sclerosis. *Can J Rehabil* 1996; 9(4):213-22. Level of Evidence: 3
190. McCabe MP, De Judicibus M. Multiple sclerosis and economic well-being: role of health, age, and duration of illness. *J Clin psychol med settings* 2003; 10(3):139-47. Level of Evidence: 3
191. Thapar N., Bhardwaj S.M. Overcoming the tyranny of space: experiences of multiple sclerosis patients. *Social work abstracts* 2000; 36(2):822. Level of Evidence: 3



Annex 1. WHO QOL Domains Matrix

	Physical Health	Psychological Health	Level of Independence	Social Relations	Environment
1.1			✓	✓	✓
1.2			✓		✓
1.3			✓		✓
1.4			✓		✓
1.5	✓	✓	✓	✓	✓
1.6					✓
2.1.1	✓	✓			✓
2.1.2	✓	✓			✓
2.2.1		✓			✓
2.2.2	✓	✓	✓		✓
2.3.1	✓	✓			✓
2.3.2	✓	✓			✓
2.3.3			✓		✓
2.3.4	✓	✓			✓
2.3.5	✓	✓			✓
2.3.6	✓	✓	✓	✓	
2.4.1	✓	✓			✓
3.1			✓		✓
3.2			✓		✓
3.3					✓
4.1	✓	✓			✓
4.2	✓	✓			
4.3	✓	✓			✓
5.1		✓			✓
5.2		✓			✓
5.3	✓	✓			✓
5.4		✓			✓
5.5		✓			✓
5.6	✓	✓			✓
6.1			✓		✓
6.2			✓		✓
7.1			✓	✓	✓
7.2			✓	✓	✓
7.3			✓		✓
7.4			✓	✓	✓
7.5			✓	✓	✓
8.1			✓		✓
8.2			✓		✓
8.3			✓		✓
9.1			✓		✓
9.2			✓		✓
9.3			✓		✓
10.1.1			✓		✓
10.1.2			✓		✓
10.1.3			✓		✓
10.2.1			✓		✓
10.2.2			✓		✓

Annex 2. Number of supporting references by level of evidence

Principle	Levels of Evidence					
	1a	1b	2a	2b	3	4
1.1					22	9
1.2				1	8	10
1.3					3	4
1.4					6	1
1.5		3		2	24	15
1.6					9	7
2.1.1					5	2
2.1.2	1	9	2	9	17	43
2.2.1				4	6	9
2.2.2					4	8
2.3.1					4	15
2.3.2		7	2	5	11	41
2.3.3				1	1	1
2.3.4					3	5
2.3.5					7	6
2.3.6		3	2	4	11	10
2.4.1		6	1	8	18	43
3.1		1			6	6
3.2					3	4
3.3						
4.1		6		3	11	16
4.2		5		1	8	21
4.3					4	5
5.1				1	24	10
5.2				1	7	4
5.3				1	18	8
5.4				1	23	12
5.5				1	5	6
5.6				1	2	2
6.1					4	4
6.2					2	2
7.1					17	14
7.2					16	12
7.3					6	2
7.4					9	9
7.5					6	2
8.1					2	2
8.2					5	2
8.3					3	2
9.1					2	
9.2						
9.3						
10.1.1					5	3
10.1.2					3	
10.1.3					4	
10.2.1					3	
10.2.2					3	

Levels of Evidence

- 1a Meta-analysis of randomized controlled trials
- 1b Randomized controlled trial
- 2a Controlled study, without randomization
- 2b Quasi-experimental study
- 3 Non-experimental, descriptive study (e.g., comparative study, correlation study, case study)
- 4 Expert committee report, opinion and/or experience of respected authority

* Evidence provided by the expert opinion of the interviewees and Oversight Group members listed in Acknowledgements.



biogen idec

MSIF would like to thank Biogen Idec for their generous grant which made the production of this publication possible.